8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 23, 2026·SEC
Arcus Biosciences, Inc.(RCUS)Earnings, Financials & Key Ratios
RCUS•NYSE
Price updated Jun 19, 2026
AboutArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.Show more
- Revenue$247M-4.3%
- EBITDA-$376M-17.5%
- Net Income-$353M-24.7%
- EPS (Diluted)-3.29-4.8%
- Gross Margin95.95%-4.0%
- EBITDA Margin-152.23%-22.7%
- Operating Margin-156.28%-22.2%
- Net Margin-142.91%-30.3%
- ROE-63.26%-5.8%
RCUS Key Insights
Arcus Biosciences, Inc. (RCUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 25.9%
✗Weaknesses
- ✗Profits declining 23.5% over 5 years
- ✗Weak Piotroski F-Score: 0/9
- ✗Negative free cash flow
- ✗Shares diluted 19.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RCUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RCUS Price & Volume
Arcus Biosciences, Inc. (RCUS) stock price & volume — 10-year historical chart
Loading chart...
RCUS Growth Metrics
Arcus Biosciences, Inc. (RCUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years25.93%
3 Years30.16%
TTM67.38%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.6%
Return on Capital
10 Years-27.85%
5 Years-25.52%
3 Years-37.02%
Last Year-42.14%
RCUS Recent Earnings
Arcus Biosciences, Inc. (RCUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.02-10.9%
$0.92
Rev
$17M-42.3%
$29M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.89+19.8%
$1.11
Rev
$33M-7.6%
$36M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$1.27+4.5%
$1.33
Rev
$26M+4.3%
$25M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.08+93.4%
$1.14
Rev
$160M+392.6%
$32M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.02vs $0.92-10.9% | $17Mvs $29M-42.3% |
| Q1 2026 | Feb 25, 2026 | $0.89vs $1.11+19.8% | $33Mvs $36M-7.6% |
| Q4 2025 | Oct 28, 2025 | $1.27vs $1.33+4.5% | $26Mvs $25M+4.3% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $1.14+93.4% | $160Mvs $32M+392.6% |
Based on last 12 quarters of dataView full earnings history →
RCUS Peer Comparison
Arcus Biosciences, Inc. (RCUS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 EXEL | 13.19B | 51.91 | 18.67 | 6.98% | 35.08% | 40.21% | 0.08 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 INCY | 19.62B | 98.22 | 15.32 | 21.22% | 26.71% | 29.31% | 0.01 |
Compare RCUS vs Peers
Arcus Biosciences, Inc. (RCUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCUS Income Statement
Arcus Biosciences, Inc. (RCUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.41M | 8.35M | 15M | 78M | 383M | 112M | 117M | 258M | 247M | 236M |
Revenue Growth % | - | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -4.26% | 67.38% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10M | 5M |
COGS % of Revenue | - | - | - | - | - | - | - | - | 4.05% | - |
Gross Profit | 1.41M▲ 0% | 8.35M▲ 491.2% | 15M▲ 79.6% | 78M▲ 420.0% | 383M▲ 391.0% | 112M▼ 70.8% | 117M▲ 4.5% | 258M▲ 120.5% | 237M▼ 8.1% | 214M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 95.95% | 90.68% |
Gross Profit Growth % | 207.53% | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -8.14% | - |
Operating Expenses | 54.85M | 63.21M | 103.71M | 202M | 329M | 392M | 457M | 588M | 623M | 629M |
OpEx % of Revenue | 3882.09% | 756.76% | 691.39% | 258.97% | 85.9% | 350% | 390.6% | 227.91% | 252.23% | - |
Selling, General & Admin | 7.64M | 13.57M | 25.23M | 43M | 72M | 104M | 117M | 120M | 110M | 111M |
SG&A % of Revenue | 540.41% | 162.41% | 168.19% | 55.13% | 18.8% | 92.86% | 100% | 46.51% | 44.53% | - |
Research & Development | 47.22M | 49.65M | 78.48M | 159M | 257M | 288M | 340M | 448M | 523M | 523M |
R&D % of Revenue | 3341.68% | 594.35% | 523.21% | 203.85% | 67.1% | 257.14% | 290.6% | 173.64% | 211.74% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20M | -10M | -2M |
Operating Income | -53.44M▲ 0% | -54.86M▼ 2.7% | -88.71M▼ 61.7% | -124M▼ 39.8% | 54M▲ 143.5% | -280M▼ 618.5% | -340M▼ 21.4% | -330M▲ 2.9% | -386M▼ 17.0% | -398M▲ 0% |
Operating Margin % | -3782.09% | -656.76% | -591.39% | -158.97% | 14.1% | -250% | -290.6% | -127.91% | -156.28% | -168.64% |
Operating Income Growth % | -193.92% | -2.65% | -61.7% | -39.78% | 143.55% | -618.52% | -21.43% | 2.94% | -16.97% | - |
EBITDA | -50.83M | -51.2M | -85.13M | -121M | 58M | -274M | -332M | -320M | -376M | -391M |
EBITDA Margin % | -3597.24% | -612.89% | -567.54% | -155.13% | 15.14% | -244.64% | -283.76% | -124.03% | -152.23% | -165.68% |
EBITDA Growth % | -201.33% | -0.72% | -66.29% | -42.13% | 147.93% | -572.41% | -21.17% | 3.61% | -17.5% | 8.22% |
D&A (Non-Cash Add-back) | 2.61M | 3.66M | 3.58M | 3M | 4M | 6M | 8M | 10M | 10M | 7M |
EBIT | -53.44M | -54.86M | -84.71M | -123M | 55M | -264M | -299M | -279M | -345M | -214M |
Net Interest Income | 775K | 4.92M | 5.2M | 1M | 1M | 14M | 39M | 48M | -8M | 32M |
Interest Income | 775K | 4.92M | 5.2M | 1M | 1M | 16M | 41M | 52M | 0 | 51M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 2M | 2M | 4M | 8M | 16M |
Other Income/Expense | 359K | 5.26M | 4M | 1M | 1M | 14M | 39M | 47M | 33M | 29M |
Pretax Income | -53.08M▲ 0% | -49.59M▲ 6.6% | -84.71M▼ 70.8% | -123M▼ 45.2% | 55M▲ 144.7% | -266M▼ 583.6% | -301M▼ 13.2% | -283M▲ 6.0% | -353M▼ 24.7% | -369M▲ 0% |
Pretax Margin % | -3756.69% | -593.73% | -564.73% | -157.69% | 14.36% | -237.5% | -257.26% | -109.69% | -142.91% | -156.36% |
Income Tax | 0 | 0 | 0 | 0 | 2M | 1M | 6M | 1M | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 3.64% | -0.38% | -1.99% | -0.35% | 0% | 0% |
Net Income | -53.08M▲ 0% | -49.59M▲ 6.6% | -84.71M▼ 70.8% | -123M▼ 45.2% | 53M▲ 143.1% | -267M▼ 603.8% | -307M▼ 15.0% | -283M▲ 7.8% | -353M▼ 24.7% | -369M▲ 0% |
Net Margin % | -3756.69% | -593.73% | -564.73% | -157.69% | 13.84% | -238.39% | -262.39% | -109.69% | -142.91% | -156.36% |
Net Income Growth % | -195.39% | 6.57% | -70.81% | -45.2% | 143.09% | -603.77% | -14.98% | 7.82% | -24.73% | 5.63% |
Net Income (Continuing) | -53.08M | -49.59M | -84.71M | -123M | 53M | -267M | -307M | -284M | -353M | -369M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.16▲ 0% | -1.43▲ 33.8% | -1.73▼ 21.0% | -2.13▼ 23.1% | 0.71▲ 133.3% | -3.71▼ 622.5% | -4.15▼ 11.9% | -3.14▲ 24.3% | -3.29▼ 4.8% | -2.94▲ 0% |
EPS Growth % | -195.89% | 33.8% | -20.98% | -23.12% | 133.33% | -622.54% | -11.86% | 24.34% | -4.78% | 24.6% |
EPS (Basic) | -2.16 | -1.43 | -1.73 | -2.13 | 0.76 | -3.71 | -4.15 | -3.14 | -3.29 | - |
Diluted Shares Outstanding | 24.55M | 34.62M | 43.83M | 54.79M | 73.97M | 72M | 74M | 90.1M | 107.4M | 125.4M |
Basic Shares Outstanding | 24.55M | 34.62M | 43.83M | 54.79M | 69.35M | 72M | 74M | 90.1M | 107.4M | 125.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RCUS Balance Sheet
Arcus Biosciences, Inc. (RCUS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 176.87M | 258.95M | 192.71M | 735.82M | 1.26B | 1.07B | 831M | 1.02B | 1.01B | 844M |
Cash & Short-Term Investments | 175.7M | 256.54M | 188.27M | 728.65M | 499.31M | 1.01B | 759M | 978M | 981M | 822M |
Cash Only | 98.43M | 71.06M | 57.94M | 173.41M | 147.91M | 206M | 127M | 150M | 222M | 201M |
Short-Term Investments | 77.28M | 185.48M | 130.33M | 555.23M | 351.39M | 803M | 632M | 828M | 759M | 621M |
Accounts Receivable | 25K | 83K | 132K | 1.7M | 746.82M | 43M | 42M | 25M | 0 | 0 |
Days Sales Outstanding | 6.46 | 3.63 | 3.21 | 7.95 | 711.72 | 140.13 | 131.03 | 35.37 | - | 13.15 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 251K | 4.47M | 14.72M | 14M | 30M | 13M | 26M | 22M |
Total Non-Current Assets | 13.62M | 15.98M | 10.4M | 36.48M | 330.15M | 279M | 264M | 134M | 132M | 153M |
Property, Plant & Equipment | 11.23M | 11.11M | 9.33M | 23.59M | 137.42M | 135M | 51M | 47M | 40M | 38M |
Fixed Asset Turnover | 0.13x | 0.75x | 1.61x | 3.31x | 2.79x | 0.83x | 2.29x | 5.49x | 6.18x | 5.76x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 682K | 4.38M | 0 | 6.64M | 185M | 134M | 107M | 14M | 0 | 26M |
Other Non-Current Assets | 1.71M | 487K | 1.07M | 6.25M | 7.73M | 10M | 106M | 73M | 92M | 115M |
Total Assets | 190.49M▲ 0% | 274.93M▲ 44.3% | 203.11M▼ 26.1% | 772.29M▲ 280.2% | 1.59B▲ 106.1% | 1.34B▼ 15.5% | 1.09B▼ 18.6% | 1.15B▲ 5.0% | 1.14B▼ 1.0% | 997M▲ 0% |
Asset Turnover | 0.01x | 0.03x | 0.07x | 0.10x | 0.24x | 0.08x | 0.11x | 0.22x | 0.22x | 0.23x |
Asset Growth % | 73.64% | 44.33% | -26.12% | 280.23% | 106.13% | -15.51% | -18.59% | 5.02% | -0.96% | -46.27% |
Total Current Liabilities | 12.73M | 16.93M | 22.71M | 121.67M | 166.08M | 193M | 184M | 226M | 231M | 209M |
Accounts Payable | 3.82M | 3.1M | 4.7M | 15.68M | 10.26M | 20M | 17M | 18M | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 1.3K |
Short-Term Debt | 0 | 0 | 0 | 2.87M | 5.1M | 3M | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 5M | 6.25M | 7M | 74.57M | 102M | 97M | 91M | 85M | 35M | 192M |
Other Current Liabilities | 769K | 1.56M | 6.43M | 19.92M | 30.26M | 48M | 39M | 14M | 196M | 175M |
Current Ratio | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x | 4.36x | 4.04x |
Quick Ratio | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x | 4.36x | 4.04x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.28K |
Total Non-Current Liabilities | 23.89M | 23.05M | 16.56M | 148.32M | 584.36M | 495M | 449M | 439M | 277M | 264M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48M | 99M | 100M |
Capital Lease Obligations | 0 | 0 | 0 | 15.24M | 116.89M | 117M | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5.3M | 6.06M | 4.54M | 10.25M | 5.26M | 23M | 142M | 157M | 178M | 164M |
Total Liabilities | 36.62M | 39.98M | 39.27M | 269.99M | 750.45M | 688M | 633M | 665M | 508M | 473M |
Total Debt | 0 | 0 | 0 | 18.11M | 121.99M | 120M | 11M | 60M | 99M | 100M |
Net Debt | -98.43M | -71.06M | -57.94M | -155.31M | -25.93M | -86M | -116M | -90M | -123M | -101M |
Debt / Equity | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x | 0.16x | 0.19x |
Debt / EBITDA | - | - | - | - | 2.10x | - | - | - | - | -0.26x |
Net Debt / EBITDA | - | - | - | - | -0.45x | - | - | - | - | 0.26x |
Interest Coverage | - | - | - | - | - | -132.00x | -149.50x | -69.75x | -43.13x | -13.38x |
Total Equity | 153.87M▲ 0% | 234.94M▲ 52.7% | 163.84M▼ 30.3% | 502.3M▲ 206.6% | 841.45M▲ 67.5% | 657M▼ 21.9% | 462M▼ 29.7% | 485M▲ 5.0% | 631M▲ 30.1% | 524M▲ 0% |
Equity Growth % | 54.7% | 52.69% | -30.26% | 206.58% | 67.52% | -21.92% | -29.68% | 4.98% | 30.1% | -7.59% |
Book Value per Share | 6.27 | 6.79 | 3.74 | 9.17 | 11.38 | 9.13 | 6.24 | 5.38 | 5.88 | 4.18 |
Total Shareholders' Equity | 153.87M | 234.94M | 163.84M | 502.3M | 841.45M | 657M | 462M | 485M | 631M | 524M |
Common Stock | 3K | 4K | 4K | 6K | 7K | 1.21B | 1.31B | 1.62B | 2.12B | 2.14B |
Retained Earnings | -73.23M | -122.83M | -205.33M | -328.18M | -275.35M | -542M | -849M | -1.13B | -1.49B | -1.61B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -42K | -107K | 64K | 44K | -1.26M | -7M | 0 | 0 | 0 | -1M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCUS Cash Flow Statement
Arcus Biosciences, Inc. (RCUS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -25.06M | -43M | -73.46M | 111.17M | -256.17M | 438M | -306M | -170M | -482M | -488M |
Operating CF Margin % | -1773.46% | -514.74% | -489.75% | 142.53% | -66.89% | 391.07% | -261.54% | -65.89% | -195.14% | - |
Operating CF Growth % | -93.6% | -71.58% | -70.86% | 251.33% | -330.43% | 270.98% | -169.86% | 44.44% | -183.53% | -539.11% |
Net Income | -53.08M | -49.59M | -84.71M | -122.86M | 52.83M | -267M | -307M | -283M | -353M | -369M |
Depreciation & Amortization | 2.61M | 3.66M | 3.58M | 4.19M | 3.84M | 14M | 8M | 10M | 10M | 9M |
Stock-Based Compensation | 495K | 3.87M | 8.98M | 22M | 55M | 0 | 73M | 76M | 60M | 63M |
Deferred Taxes | 416K | -2.1M | 0 | 0 | 4.77M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -98K | -177K | -1.44M | -46K | 3.47M | 68M | -9M | 5M | -5M | -34M |
Working Capital Changes | 24.6M | 1.33M | 125K | 208.06M | -375.62M | 623M | -71M | 22M | -194M | -157M |
Change in Receivables | 380K | -58K | -49K | -917K | -17.05M | 704M | 15M | 28M | 9M | 4M |
Change in Inventory | 0 | 0 | 0 | 21.32M | 14.09M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -267K | -69K | 1.73M | 9.27M | -4.77M | 8M | -1M | 3M | 24M | 18M |
Cash from Investing | -49.07M | -113.44M | 59.21M | -434.37M | -3.87M | -413M | 194M | -84M | 66M | 148M |
Capital Expenditures | -5.51M | -3.74M | -1.93M | -3.06M | -26.08M | -6M | -24M | -6M | -2M | -1M |
CapEx % of Revenue | 390.23% | 44.81% | 12.83% | 3.92% | 6.81% | 5.36% | 20.51% | 2.33% | 0.81% | 0.42% |
Acquisitions | 0 | 0 | 0 | 431M | -22M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -43.56M | -109.7M | 0 | -431M | 22M | -3M | 0 | 0 | 0 | 0 |
Cash from Financing | 107.4M | 129.07M | 1.12M | 438.68M | 237.34M | 33M | 33M | 277M | 488M | 349M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 5M | 10M | 0 | 47M | 49M | 49M |
Equity Issued (Net) | 106.88M | 125.11M | -94K | 434M | 220M | 23M | 25M | 228M | 439M | 297M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -94K | -54K | -6K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 519K | 3.96M | 1.22M | 4.67M | 12.34M | 0 | 8M | 2M | 0 | 3M |
Net Change in Cash | 33.27M▲ 0% | -27.36M▼ 182.3% | -13.13M▲ 52.0% | 115.48M▲ 979.7% | -22.7M▼ 119.7% | 58.09M▲ 355.9% | -79M▼ 236.0% | 23M▲ 129.1% | 72M▲ 213.0% | 9M▲ 0% |
Free Cash Flow | -30.57M▲ 0% | -46.74M▼ 52.9% | -75.39M▼ 61.3% | 108.11M▲ 243.4% | -282.25M▼ 361.1% | 432M▲ 253.1% | -330M▼ 176.4% | -176M▲ 46.7% | -484M▼ 175.0% | -489M▲ 0% |
FCF Margin % | -2163.69% | -559.55% | -502.58% | 138.61% | -73.69% | 385.71% | -282.05% | -68.22% | -195.95% | -207.2% |
FCF Growth % | -79.39% | -52.88% | -61.29% | 243.41% | -361.06% | 253.06% | -176.39% | 46.67% | -175% | -61.39% |
FCF per Share | -1.25 | -1.35 | -1.72 | 1.97 | -3.82 | 6.00 | -4.46 | -1.95 | -4.51 | -3.90 |
FCF Conversion (FCF/Net Income) | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x | 1.37x | 1.33x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCUS Key Ratios
Arcus Biosciences, Inc. (RCUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -41.91% | -25.51% | -42.48% | -36.93% | 7.89% | -35.64% | -54.87% | -59.77% | -63.26% | -68.97% |
Return on Invested Capital (ROIC) | -89.32% | -37.52% | -49.32% | -41.07% | 6.97% | -30.29% | -55.62% | -66.8% | -64.12% | -72.36% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 95.95% | 90.68% |
Net Margin | -3756.69% | -593.73% | -564.73% | -157.69% | 13.84% | -238.39% | -262.39% | -109.69% | -142.91% | -156.36% |
Debt / Equity | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x | 0.16x | 0.19x |
Interest Coverage | - | - | - | - | - | -132.00x | -149.50x | -69.75x | -43.13x | -13.38x |
FCF Conversion | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x | 1.37x | 1.33x |
Revenue Growth | - | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -4.26% | 67.38% |
Related:RCUS Dividend History·RCUS Revenue History·RCUS Price History·RCUS P/E History·RCUS Financial Ratios·RCUS Institutional Holders
RCUS SEC Filings & Documents
Arcus Biosciences, Inc. (RCUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
RCUS Frequently Asked Questions
Arcus Biosciences, Inc. (RCUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcus Biosciences, Inc. (RCUS) reported $236.0M in revenue for fiscal year 2025.
Arcus Biosciences, Inc. (RCUS) saw revenue decline by 4.3% over the past year.
Arcus Biosciences, Inc. (RCUS) reported a net loss of $369.0M for fiscal year 2025.
Dividend & Returns
Arcus Biosciences, Inc. (RCUS) has a return on equity (ROE) of -63.3%. Negative ROE indicates the company is unprofitable.
Arcus Biosciences, Inc. (RCUS) had negative free cash flow of $489.0M in fiscal year 2025, likely due to heavy capital investments.